Obagi Medical Partners with Next Health for Real-World Evidence Study on saypha® MagIQ™
Event summary
- Obagi Medical, part of Waldencast plc, has partnered with Next Health to evaluate the Obagi® saypha® MagIQ™ filler in real-world settings through the ALOHA Program.
- Next Health will conduct a multi-site assessment across its wellness centers, focusing on clinical efficacy and patient experience.
- Initial findings from the program are expected to be presented at industry conferences later this year.
The big picture
This collaboration underscores the increasing convergence of aesthetic medicine and longevity wellness, as Obagi Medical seeks to strengthen its evidence-based approach in a competitive market. The partnership aligns with broader industry trends where data-driven outcomes are becoming critical for patient trust and provider adoption.
What we're watching
- Market Expansion
- How Obagi Medical’s collaboration with Next Health will influence its positioning in the growing longevity and wellness market.
- Data-Driven Strategy
- Whether the real-world evidence generated from this partnership can drive broader adoption of saypha® MagIQ™ among aesthetic practitioners.
- Industry Impact
- The pace at which similar partnerships emerge as more wellness centers seek to integrate advanced injectables with holistic care protocols.
Related topics